Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8483326 | 0.95 | CTSK (0.55) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL17793196 | 0.94 | CA1 (0.56) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL16055278 | 0.91 | CTSK (0.51) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL21847055 | 0.90 | DRD2 (0.52) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL359644 | 0.90 | CTSK (0.64) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL428907 | 0.90 | CTSK (0.64) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL1959133 | 0.90 | CTSK (0.64) | CTSKBTKDRD2CA1CA2 | |
| Hydrochloric Acid SCHEMBL27630477 | 0.88 | CTSK (0.62) | CTSKBTKDRD2CA1CA2 | |
| Piperidine SCHEMBL27605900 | 0.88 | CTSK (0.49) | CTSKBTKDRD2CA1CA2 | |
| SCHEMBL24068416 | 0.86 | CTSK (0.59) | CTSKBTKDRD2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105829293-A | Novel piperidine carboxamide compound, preparation method, and usage thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2016-08-03 | — | — | CN | claimed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118076610-A | Macrocyclic compounds with ENT1 inhibitory activity | ITEOS比利时公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117957225-A | Compounds for targeting degradation of IRAK4 proteins | 渤健马萨诸塞州股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117916235-A | Cyclin dependent kinase inhibitors | 泰州亿腾景昂药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-1228083-A | Arylsulfonylamino hydroxamic acid derivatives | PFIZER (US) | 1999-09-08 | — | — | CN | disclosed |
| CN-1223659-A | Fused imidazopyridine derivatives as antihyperlipidemic agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| EP-0922030-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998007697-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | CTSK 598/4885BTK 829/4885DRD2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.